Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy

Wound Repair and Regeneration

Volumn 8, Issue 3, 2000, Pages 162-168

  Embil, John M ^a   Papp, Kim ^b   Sibbald, Gary ^c   Tousignant, Jacqueline ^d   Smiell, Janice M ^e   Wong, Betty ^f   Lau, Cathy Y ^f  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e R W JOHNSON PHARMACEUTICAL RES I   (United States)

^f Janssen Ortho Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLATELET DERIVED GROWTH FACTOR BB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCER HEALING;

CHRONIC DISEASE; DIABETIC FOOT; GELS; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; TREATMENT OUTCOME; WOUND HEALING;

EID: 0033945354     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.2000.00162.x     Document Type: Article

References (29)

1. King H, Aubert RE, Herman WH. Global burden of diabetes. 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. James R, Young TK, Mustard CA, Blanchard J. The health of Canadians with diabetes. Health Reports 1997;9:47-52.
3. American Diabetes Association. Diabetes 1996: vital statistics. Alexandria, VA: American Diabetes Association, 1996.
4. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998;21:42-8.
5. Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991;40:1305-13.
6. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513-21.
7. Young MJ, Veves A, Boulton AJM. The diabetic foot: aetiopathogenesis and management. Diabetes Metab Rev 1993;9:109-27.
8. Schaffer CJ, Narrey LB. Cell biology of wound healing. Int Rev Cytol 1996;169:151-81.
9. Wahl LM, Wahl SM. Inflammation. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing: biochemical and clinical aspects. Philadelphia: W.B. Saunders Company, 1992: 40-60.
10. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996;41:159-67.
11. McKay IA, Leigh IM. Epidermal cytokines and their roles in cutaneous wound healing. Br J Dermatol 1991;124:513-8.
12. Bennett NT, Schultz GS. Growth factors and wound healing: part II. Role in normal and chronic wound healing. Am J Surg 1993; 166:74-81.
13. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319-26.
14. Knighton DR, Doucette M, Fiegel VD, Ciresi K, Butler E, Austin L. The use of platelet derived wound healing formula in human clinical trials. Prog Clin Biol Res 1988;266:319-29.
15. Grotendorst GR, Martin GR, Pencev D, Sodek J, Harvey AK. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J Clin Invest 1985;76:2323-9.
16. Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg 1998;176 (Suppl.):74S-9S.
17. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg 1999;7:335-46.
18. Steed DL, the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995;21: 71-81.
19. d'Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethylcellulose aqueous-based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998;10: 69-75.
20. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III, randomized, placebo-controlled, double-blind study. Diabetes Care 1998;21:822-7.
21. Grunfeld C. Diabetic foot ulcers: etiology, treatment, and prevention. Adv Intern Med 1991;37:103-32.
22. The National Pressure Ulcer Advisory Panel. Pressure ulcers prevalence, cost and risk assessment: consensus development conference statement. Decubitus 1989;2:24-8.
23. Orchard TJ, Strandness DEJ. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association 18-20 September 1992, New Orleans, Louisiana Diabetes Care 1993; 16:1199-209.
24. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22:692-5.
25. McMichael AJ, Griffiths CEM, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, Voorhees JJ. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996;135:60-4.
26. White J. Therapeutic footwear for patients with diabetes. J Am Podiatr Med Assoc 1994;84:470-9.
27. Chantelau E, Haage P. An audit of cushioned diabetic foot wear: relation to patient compliance. Diabetes Spectrum 1995;8:228-9.
28. Knowles EA, Boulton AJ. Do people with diabetes wear their prescribed footwear? Diabet Med 1996;13:1064-8.
29. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care 1998;21: 2161-77.